Key result
Torsemide was not associated with a significant difference in intermediate-term mortality compared with furosemide (OR 1.01; 95% CI 0.64-1.59), but reduced heart failure readmissions.
Why the study?
Loop diuretics are a mainstay of chronic heart failure management, but evidence regarding the optimal choice between furosemide and torsemide for clinical outcomes remains inconsistent.
Does oral torsemide improve intermediate-term outcomes compared to oral furosemide in patients with chronic heart failure?
Population
8127 chronic heart failure patients across 14 studies
Comparison
Oral torsemide vs oral furosemide
Follow-up
5-12 months
Authors
Loading...
Torsemide may improve NYHA class versus furosemide in HF; leaves open effects on mortality or hospitalizations.
Meta-Analysis (n=8,127)
Does oral torsemide improve intermediate-term outcomes compared to oral furosemide in patients with chronic heart failure?
Odds Ratio: 1.01 (95% CI 0.64–1.59)
In patients with chronic heart failure, torsemide is associated with reduced heart failure readmissions and improved NYHA class compared to furosemide, though without a significant difference in intermediate-term mortality.
Miles et al. (2019) conducted a meta-analysis in chronic heart failure (n=8,127). Torsemide vs. Furosemide was evaluated on intermediate-term mortality (OR 1.01, 95% CI 0.64-1.59). Torsemide was not associated with a significant difference in intermediate-term mortality compared with furosemide (OR 1.01; 95% CI 0.64-1.59), but reduced heart failure readmissions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: